Cochlear stock gets a Hold call as FY26 risks persist

Published on 10/08/2026 at 06:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ord Minnett kept its Hold rating on October 5 with an AUD 138.00 target, while Cochlear stock traded at AUD 129.21 on October 8. FY2026 net income fell 62 percent.

Cochlear, AU000000COH5, Illustration mit AI erstellt.

Cochlear stock (ISIN AU000000COH5) was trading at AUD 129.21 on the ASX on October 8, 2026, at 3:15 p.m. AEDT, down 0.22 percent from the prior close. The latest analyst action keeps the valuation debate centered on weaker FY2026 earnings and the company’s legal exposure.

Hold rating leaves limited upside

Ord Minnett maintained a Hold rating on October 5 and set an AUD 138.00 price target, according to Markets Insider. The target lies 6.8 percent above the ASX price of AUD 129.21, giving the analyst call a modest numerical gap rather than a broad directional signal.

The same report said the analyst consensus was Hold with an average target of AUD 139.80, according to Markets Insider. That average target is 8.2 percent above the October 8 trading price.

FY2026 profit reset remains central

Cochlear’s FY2026 revenue was AUD 2.35 billion, flat from FY2025, while net income fell 62 percent to AUD 147.3 million and earnings per share declined to AUD 2.25 from AUD 5.94, according to Simply Wall St. The figures show why price targets remain sensitive to margin recovery and implant demand.

A shareholder class action added a legal dimension to the earnings reset. Reuters reported on September 29 that Cochlear had been served with a claim in Victoria’s Supreme Court over its FY2026 underlying net profit forecast, allegations the company denied and said it would defend. Reuters also reported that the forecast had been cut to AUD 290 million to AUD 330 million from AUD 435 million to AUD 460 million in April.

Stock trades near the lower half

The October 8 trading range was AUD 127.83 to AUD 130.96, while the 52-week range was AUD 88.74 to AUD 296.50. Cochlear’s market capitalization was AUD 8.5 billion and volume stood at 146,834 shares on October 8, 2026.

For investors, the contrast is clear: the stock is far below its 52-week high, while the current analyst targets remain above the market price and the FY2026 earnings base is materially lower than a year earlier.

ASX price and company facts

Cochlear was last trading at AUD 129.21 on the ASX on October 8, 2026, at 3:15 p.m. AEDT. The company develops implantable hearing solutions and operates in the healthcare and medical device industry.